Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OPEN LABEL PHASE 2 STUDY ON THE EFFICACY AND TOLERANCE OF A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS - PONAZA TRIAL

NCT03895671 is registered in ClinicalTrials.gov with Versailles Hospital as lead sponsor.

NCT NCT03895671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03895671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OPEN LABEL PHASE 2 STUDY ON THE EFFICACY AND TOLERANCE OF A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS - PONAZA TRIAL
Lead sponsor
Versailles Hospital
Phase
Phase 2
Overall status
Completed
Start date
June 19, 2019
Completion date
December 31, 2025
Enrollment
32 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelogenous leukaemia in accelerated phase, chronic myelogenous leukaemia in myeloid blast crisis